Ginsenoside Rh4 prevents endothelial dysfunction as a novel AMPK activator.
Jiawei ZhangWeiqiang LvXuyun LiuZhenyu SunMengqi ZengJiahao KangQi ZhangFuying LiuShaozhou MaXiaolong LiKe CaoJiankang LiuPublished in: British journal of pharmacology (2024)
Rh4 may serve as a novel AMPK activator to protect against hyperlipidaemia-induced endothelial dysfunction, providing new insights into the prevention and treatment of endothelial injury-associated CVD.